Dr. Eyre on Resistance to BTK Inhibition in MCL

Video

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).

In a study presented at the 2018 European Hematology Association Congress, venetoclax (Venclexta) monotherapy induced an overall response rate (ORR) of 60% in patients with poor-risk relapsed/refractory MCL previously treated with a BTK inhibitor. Patients who develop resistance to BTK inhibitors are a big unmet need in MCL, explains Eyre, accounting for approximately 30% of the overall population.

In a phase II study with ibrutinib (Imbruvica) monotherapy (NCT01236391), the ORR in relapsed/refractory patients was 68%, with a complete response of 21%, which left approximately 30% of patients with no suitable treatment alternatives. Additionally, the progression-free survival was just over 1 year, suggesting that many of the patients who do respond to the inhibitor will experience relapse. Within 1 or 2 years of BTK inhibitor therapy, the majority of patients will require another line of therapy, explains Eyre.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD